We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
Newsletter 2019 Summer Edition

1300 members from 70 countries Join ICRS

News

The ICRS Newsletter Summer 2019 Issue is now out. Hard copies will be delivered to our members and partners worldwide in the next few days. Enyoy Reading

Newsletter 2019 Summer Edition

Newsletter 2019 Summer Edition

05/07/2019

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

01/09/2017